Teruhisa Kato

7PUBLICATIONS
27CO-AUTHORS
Biologically active moleculesMedical biotechnology diagnostics (incl. biosensors)Proteins and peptidesMolecular medicineCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 05, 2025
Discovery of the Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19.

Yuto Unoh, Keiichiro Hirai, Shota Uehara

|Nov 19, 2024
Accelerating Antimalarial Drug Discovery with a New High-Throughput Screen for Fast-Killing Compounds.

Takaya Sakura, Ryuta Ishii, Eri Yoshida

|Nov 17, 2023
Peptide-to-Small Molecule: Discovery of Non-Covalent, Active-Site Inhibitors of β-Herpesvirus Proteases.

Shuhei Yoshida, Yusuke Sako, Eiji Nikaido

|Oct 28, 2023
Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.

Keita Fukao, Haruaki Nobori, Takayuki Kuroda

|Feb 10, 2023
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.

Takayuki Kuroda, Haruaki Nobori, Keita Fukao

|Nov 03, 2022
S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.

Michihito Sasaki, Koshiro Tabata, Mai Kishimoto

Pageof 2

Frequent Collaborators

4 joint publications

Haruaki Nobori

4 joint publications

Yuki Tachibana

2 joint publications

Takao Sanaki

2 joint publications

Hirofumi Sawa